LNCRNA-ATB

Summary

LNCRNA-ATB (lncRNA activated by TGF-beta, HGNC:52657) is a long non-coding RNA gene on chromosome 14q11.2.

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:52657
Approved symbol	LNCRNA-ATB
Name	lncRNA activated by TGF-beta
Location	14q11.2
Locus type	RNA, long non-coding
Status	Approved
Entrez	114004396
RNAcentral	URS0000E60A46 — lncRNA, 2445 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 33)

• LncRNA-ATB was discovered in 2014 and named as a lncRNA activated by TGF-beta. LncRNA-ATB can induce EMT in several types of cancer by competitively binding miR- 200 family. (PMID:24768205)
• Results show that ATB is abnormally up-regulated both in glioma tissues and cell lines compared with normal brain tissues. Its knockdown significantly inhibits glioma malignancy, including cell proliferation, colony formation, migration, invasion in vitro, and the xenograft tumor formation in vivo. Also, ATB was confirmed to target miR-200a. (PMID:27267902)
• The overall survival and progression-free survival were significantly lower in hepatocellular carcinoma (HCC) patients with higher circulating levels of exosomal miRNA-21 and lncRNA-ATB. In conclusion, study has provided strong evidence that circulating exosomal ncRNAs (miRNA-21 and lncRNA-ATB) are novel prognostic markers and therapeutic targets for HCC. (PMID:30338850)
• results show that knockdown of lnc-ATB significantly inhibits the EMT process of breast cancer cells by increasing the expression of miR-141-3p, indicating that lnc-ATB might serve as a novel therapeutic target for breast cancer. (PMID:30352165)
• astrocytes activated by lncRNAATB in turn promoted the migration and invasion of glioma cells. Taken together, the findings of this study suggest that lncRNAATB may play an important role in modulating glioma microenvironment through exosomes. (PMID:30483768)
• downregulation of lncRNA-ATB in serum is a reliable diagnostic marker for osteoarthritis (PMID:30505322)
• Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axis and predicts poor prognosis in breast cancer. (PMID:30518916)
• that high expression of lncRNA ATB could accelerate the proliferative and migratory rates of RCC cells and inhibit cell apoptosis through downregulating p53 via binding to DNMT1 (PMID:30536843)
• We demonstrated that ITGA6 was a direct target of miR-144, and lncRNA ATB facilitated the proliferation and invasion of cervical cancer cells via the miR-144/ITGA5 axis. (PMID:30908730)
• TGF-beta1 and lncRNA-ATB expression was upregulated in patients with atherosclerosis, and increased expression levels of TGF-beta1 and lncRNA-ATB may be used to effectively distinguish atherosclerosis patients from normal healthy individuals. (PMID:30942415)
• IL-11 mediated by lnc-ATB increased the proliferation and invasion of ESCC cells. (PMID:30954889)
• Our results suggested a significant accuracy of lncRNA-ATB and lncRNA-CCAT1 in distinguishing colorectal cancer patients from healthy individuals. (PMID:31093977)
• this study revealed that lncRNA-ATB promotes TGF-beta-induced glioma cell invasion (PMID:31140621)
• Regulatory effects of lncRNA ATB targeting miR-200c on proliferation and apoptosis of colorectal cancer cells. (PMID:31222825)
• The expression of lncRNA-ATB was higher in hepatocellular carcinoma (HCC) tissues than in normal liver, and lncRNA-ATB expression was positively correlated with tumor size, TNM stage, and poorer survival. LncRNA-ATB promoted autophagy by activating Yes-associated protein (YAP). Moreover, lncRNA-ATB interacted with autophagy-related protein 5 (ATG5) mRNA and increased ATG5 expression. (PMID:31558875)
• HBxassociated long noncoding RNA activated by TGFbeta promotes cell invasion and migration by inducing autophagy in primary liver cancer. (PMID:31746419)
• lncRNA-ATB overexpression promotes mesenchymal phenotype in lung squamous carcinoma cells by modulating the microRNA-590-5p/NF-90 axis. (PMID:31934791)
• Study suggests that lncRNA-ATB promotes the apoptosis of NSCLC cells through inhibiting the expression of miR-200a and reversely promoting the expression of beta-catenin. (PMID:31983095)
• lncRNA-ATB was significantly up-regulated in non-small cell lung cancer (NSCLC) tissues and cell lines, and high lncRNA-ATB expression indicated poor prognosis. Knockdown of lncRNA-ATB suppressed NSCLC cell growth, colony formation, migration, invasion and reversed epithelial-mesenchymal transition. Further mechanism studies demonstrated that miR-141-3p was the target of lncRNA-ATB. (PMID:32092085)
• Prognostic impact of lncRNA-ATB expression in malignant solid tumors: A meta-analysis. (PMID:32146004)
• Prognostic value of long non-coding RNA ATB in digestive system cancers: A meta-analysis. (PMID:32307201)
• Long Non-Coding RNA (LncRNA)-ATB Promotes Inflammation, Cell Apoptosis and Senescence in Transforming Growth Factor-beta1 (TGF-beta1) Induced Human Kidney 2 (HK-2) Cells via TGFbeta/SMAD2/3 Signaling Pathway. (PMID:32447340)
• Long Non-Coding RNA-ATB Attenuates the Angiotensin II-Induced Injury of Vascular Endothelial Cell. (PMID:32581029)
• Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer. (PMID:32763293)
• The prognostic value of long noncoding RNA activated by TGF-beta in digestive system cancers: A meta-analysis. (PMID:32791727)
• LncRNA-AK149641 regulates the secretion of tumor necrosis factor-alpha in P815 mast cells by targeting the nuclear factor-kappa B signaling pathway. (PMID:33024135)
• Expression of lncRNA-ATB in laryngeal carcinoma and its relationship with prognosis. (PMID:33215432)
• Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2. (PMID:33336896)
• LncRNA-ATB regulates epithelial-mesenchymal transition progression in pulmonary fibrosis via sponging miR-29b-2-5p and miR-34c-3p. (PMID:34180127)
• Identification of plasma lncRNA-ATB levels in hepatitis B virus-related cirrhosis and non-cirrhotic chronic hepatitis B patients. (PMID:34331990)
• LncRNA-ATB participates in the regulation of calcium oxalate crystal-induced renal injury by sponging the miR-200 family. (PMID:34736391)
• Study on the Expression of lncRNA ATB and Nek9 in Breast Cancer Patients Based on Q-PCR Technology and Its Relationship with the Disease. (PMID:35935324)
• Long non-coding RNA ATB expedites non-small cell lung cancer progression by the miR-200b/fibronectin 1 axis. (PMID:36806318)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1005476217 (14:19125962 C>A,T), RS1007364845 (14:19127736 C>T), RS1007497603 (14:19129159 A>G), RS1010649344 (14:19127777 C>G), RS1010786719 (14:19129390 A>G), RS1016978105 (14:19125898 C>A,T), RS1018832216 (14:19129069 A>G,T), RS1019280017 (14:19127730 A>C), RS1022132231 (14:19129384 C>A,T), RS1025630525 (14:19127401 C>G,T), RS1026627092 (14:19126120 G>A), RS1035184686 (14:19125712 G>A,T), RS1040198702 (14:19126398 A>G), RS1040633936 (14:19125278 T>C), RS1043470255 (14:19127771 G>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 0 entries

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Silicon Dioxide	increases expression, increases secretion	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.